Saving changes...

Done

Error

Immunotherapies in Oncology: Implications in Managed Care for the Treatment of Melanoma and NSCLC

Immunotherapies in Oncology: Implications in Managed Care for the Treatment of Melanoma and NSCLC

Immunotherapies in Oncology: Implications in Managed Care for the Treatment of Melanoma and NSCLC

Val R. Adams, PharmD,  FCCP, BCOP
Val R. Adams, PharmD, FCCP, BCOP
on behalf of Postgraduate Healthcare Education, LLC

FREE
FREE
FREE

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 13 Mar 2017
Expiry Date:

Last updated: 15 Mar 2017

Reference: 172117

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

The use of immunotherapies promises improved outcomes for cancer patients. However, their mechanisms of action (MOAs), response patterns and adverse event (AE) management strategies differ greatly from traditional chemotherapies and even the newer targeted therapies. Cytotoxic chemotherapy, which has long been a mainstay of cancer treatment, indiscriminately attacks all dividing cells. In contrast to this, targeted therapies interfere with specific pathways needed for tumor growth. Immunotherapies, which represent a novel type of targeted therapy, are the result of an immune response generated in the patient. Although active immunotherapeutics were initially approved for melanoma, their roles have been expanded to include treatment of non-small cell lung cancer (NSCLC). The survival benefits of new and emerging immunotherapies are accompanied by high drug costs, making formulary decisions complex. As these treatments are relatively new, long-term data is not available, leading to questions regarding the durability of response. Other questions affecting payers and contributing to formulary decisions include the usefulness of biomarkers to match patients to immunotherapies, combined use of immunotherapy with other classes of drugs or other immunotherapies, the use of immunotherapies in patients with comorbidities or advanced age, the effects of therapy on patient-reported quality of life, and the limited comparative effectiveness data on available immunotherapies. This archived symposium will present the most up-to-date information on the use of immunotherapies in melanoma and NSCLC, their unique MOAs, response patterns and AE management strategies. Oncology pharmacist experts will address issues and challenges in incorporating these therapies into clinical practice to positively impact patient outcomes.

Objectives

Objectives
At the conclusion of this activity, the participant should be able to:

-EVALUATE the efficacy and safety of immunotherapy as part of melanoma and NSCLC treatment paradigms.
-RECOGNIZE unique disease response patterns and adverse event management associated with immunotherapy treatment.
-DESCRIBE pharmacy-driven management strategies to optimize treatment plans for melanoma and NSCLC.
Val R. Adams, PharmD,  FCCP, BCOP

Author Information Play Video Bio

Val R. Adams, PharmD, FCCP, BCOP
on behalf of Postgraduate Healthcare Education, LLC

Val R. Adams, PharmD, FCCP, BCOP Associate Professor Pharmacy Practice and Science Department College of Pharmacy University of Kentucky Lexington, Kentucky

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.50 Hours -
    Exam Pass Rate: 75
    -
    Reference: 0064-0000-16-224-H01-P

Faculty and Disclosures

Additional Contributors

null

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error